Novartis to build biotech facility in Singapore

- Last updated on GMT

Novartis invests in Singapore
Novartis invests in Singapore
Novartis will spend $500m on a new cell-culture based manufacturing facility in Singapore.

The new biologics plant, which is due to be operational by 2016, will be built next to a solid dose pharmaceutical production facility that Novartis set up at the Tuas Biomedical Park​ in 2005.

The plan is to handle clinical and commercial production of monoclonal antibody-based medicines for autoimmune, respiratory and oncology indications.

CEO Joe Jimenez said that: "We have chosen Singapore as strategic supply point as it offers a wide range of advantages due to its strong local biomedical presence and knowledge, skilled labour as well as proximity to growth markets in Asia."

in-Pharmatechnologist.com asked Novartis if the plant is different from the one it said it would build in 2007​, but the firm did not respond to the request for information.

Related topics: Processing

Related news

Show more